Peptide Library

Multi-peptide blend research

Glow Stack 2 mL multi-dose pen

Research-onlyEvidence: Preclinical

A combination presentation of GHK-Cu, BPC-157 and TB-500. Each component is a research compound; the combination itself has not been studied as a product in people.

What it is

A multi-peptide research presentation combining GHK-Cu, BPC-157 and TB-500 in one pen. It is not a registered medicine and is not authorised for supply to the public.

Mechanism being studied

The components appear separately in extracellular-matrix, tissue-repair and cytoskeletal research. The combination has no published mechanism of its own.

Human evidence

No controlled human trials of this combination exist. Skin, hair or appearance claims made for injectable combinations of this kind are not supported by adequate human evidence.

Safety considerations

Interaction effects between the components have not been characterised. Safety information for this compound is incomplete outside of controlled settings. Reported considerations in the literature include injection-site reactions, unknown long-term effects, product-quality and sterility risks with unregistered preparations, and unpredictable interactions with existing medicines or conditions. Any consideration of use belongs with a registered healthcare professional who can assess the individual clinical picture.

Regulatory status

Research-only. Not approved anywhere for human therapeutic use. Prohibited in sport.

Evidence & Regulation

Where the evidence for Glow Stack sits, and the rules that apply to it

Every source below is a public, primary source — a literature index, a trials registry, or a regulator. They are reading directions for professionals, not endorsements, and they do not establish that any use of Glow Stack is approved, safe or appropriate.

Citations

Further reading

  • Component literature for GHK-Cu, BPC-157 and thymosin beta-4 indexed in PubMed.
  • SAHPRA — guidance on unregistered health products.

How the regulation works

Registration comes before supply

In South Africa, a product intended to treat, prevent or otherwise affect the functioning of the body is a medicine and must be registered with SAHPRA before it may lawfully be sold. An unregistered compound cannot be advertised or supplied to the public, regardless of the evidence behind it.

SAHPRA — medicines registration

Section 21 is the professional access route

Where no registered alternative exists, a registered healthcare professional may apply to SAHPRA under Section 21 for authorisation to access an unregistered product for a named patient. That application is made by the clinician, not by the patient, and not by us.

Section 21 pathway

Prescription and dispensing stay with licensed channels

Any prescribing decision, dosing decision and dispensing step belongs to a registered healthcare professional and a licensed pharmacy. We publish reference information and analytical documentation only, and never dosing, protocols or self-administration guidance.

Prohibited in sport

Non-approved substances are prohibited at all times under the World Anti-Doping Code, including many research peptides. Athletes under testing jurisdiction should treat every compound on this site as prohibited unless their governing body confirms otherwise.

WADA Prohibited List

Status is jurisdiction-specific

A compound may be an approved medicine in one country, an investigational agent in a second, and an unregistered research chemical in a third. Always confirm the classification that applies where you practise before acting on any information here.

EMA medicines database

Information only — availability subject to applicable law, prescription/authorisation, and licensed healthcare/pharmacy channels. Nothing on this page is an offer to sell, and no dosing or self-administration guidance is provided.

South Africa — compliance notice

SAHPRA has publicly warned about unregistered peptide products being marketed to the South African public. In general, products intended to diagnose, treat, or otherwise alter bodily functions require registration or authorisation before they may lawfully be sold. ELLIVON BIOSCIENCES publishes reference information only and directs all clinical questions to registered healthcare professionals and licensed pharmacy channels.